Cannabinoid-based medicine Epidiolex approved for sale in Canada

Canada’s federal health regulator has approved Jazz Pharmaceuticals Canada’s cannabinoid-based medicine Epidiolex as an adjunctive therapy for certain rare and severe forms of epilepsy, allowing the company to bring to market a clinically tested drug with global sales that dwarf those of the nation’s entire medical cannabis industry

Lawsuit: Generic drugmakers infringed on Epidiolex cannabis drug patents

Global pharma giant Jazz Pharmaceuticals filed a lawsuit alleging that a list of generic drug companies infringed on its patents for Epidiolex, a cannabis-derived drug used to treat seizures from Dravet syndrome, tuberous sclerosis complex and Lennox-Gastaut syndrome.

Denmark medical cannabis sales post a positive quarter thanks to Epidiolex

Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the launch of GW Pharmaceuticals’ cannabis drug Epidiolex.

Epidiolex maker GW Pharma reports record quarterly revenue of $137 million

United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its cannabidiol medicine Epidiolex.

DEA removes cannabis drug Epidiolex from controlled substances list

Epidiolex, the only plant-derived cannabis drug approved by the U.S. Food and Drug Administration, is no longer considered a controlled substance, providing a boost to its manufacturer’s stock price.

Australia expedites review of medical cannabis product Epidiolex

The only medical cannabis product in the Australian Register of Therapeutic Goods might soon be joined by another.

Epidiolex, Sativex maker GW Pharma reports Q1 revenue, loss improvement

United Kingdom-based GW Pharmaceuticals showed revenue of $39.2 million for the quarter ended March 31, 2019, compared with $3 million in the same period a year ago.

Rescheduling could foster marijuana acceptance from health care industry

Moving marijuana from Schedule 1 to Schedule 3 under the Controlled Substances Act could influence whether and how doctors recommend medical cannabis.

Japan prepares medical cannabinoids law similar to Korea’s

A draft law in Japan to legalize some pharmaceutically derived medical cannabinoid medicines, while bolstering criminal penalties for marijuana use, has been approved by the country’s House of Representatives.